Business Context and Reporting Period
Company: Corvus Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 11, 2016
Event: Announcement of preliminary Phase 1/1b clinical data for the lead checkpoint inhibitor CPI-444, presented at the Society for Immunotherapy of Cancer's (SITC) 31st Annual Meeting.
Key Financial Metrics
This filing is a current report regarding a corporate event and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is the release of clinical data indicating that CPI-444 demonstrated safety and evidence of anti-tumor activity as a single agent in patients with advanced refractory cancers. No financial changes versus prior periods are reported in this document.
Outlook, Risks, and Management Commentary
- Management Commentary: The company highlighted the safety profile and anti-tumor activity of CPI-444 based on the preliminary data.
- Unusual Items: None reported in this filing.
- Risks and Contingencies: This specific 8-K does not detail new risks or contingencies beyond the inherent uncertainties of clinical development implied by the "preliminary" nature of the data.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for detailed clinical trial results and patient response rates.
- Verify the specific indications and patient populations included in the Phase 1/1b study.
- Check subsequent filings for updates on the regulatory pathway or next-phase trial designs for CPI-444.
- Confirm the company's cash runway and funding status in the most recent 10-Q or 10-K, as this 8-K contains no financial data.